An observational study in Metastatic Breast Cancer, Circulating Tumor DNA and Gene Abnormality, sponsored by Hunan Cancer Hospital. Completed. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-06-22.
Sponsored by Hunan Cancer Hospital · Observational
This is a retrospective, observational, multi-center clinical study of circulating tumor DNA (ctDNA) to guide late-line therapy in late-stage metastatic breast cancer patients.
This study aims to evaluate the feasibility of plasma ctDNA mutation in guiding late-line treatment for late-stage metastatic breast cancer patients. Meanwhile, this study tries to evaluate the curative effect of ctDNA subtype-guided late-line therapy.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's enrollment of 223 is above the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Hunan Cancer Hospital is the lead sponsor of 54 studies on the registry; 28 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This cohort study recruited consecutive patients with recent progression of metastatic TNBC after multiple lines of chemotherapy or of HR+ or HER2+ metastatic breast cancer after multiple lines of endocrine or targeted therapy.
Exclusion Criteria:
Control group includes patients without ctDNA abnormality and patients without druggable ctDNA abnormality.
Drug: Control group
Case group includes patients with druggable ctDNA abnormality.
Drug: Case group
Physician chosen treatment
Druggable ctDNA alterations-guided therapy
Also known as: PARP inhibtior, EGFR inhibitor, CDK4/6 inhibitor, AR antagonists, anti-VEGFR, anti-FGFR, Fulvestrant, ADC drugs, PI3K inhibitor, anti-HER2 treatment, HDAC inhibitor
Disease Control Rate (DCR)
The total rate of CR+PR+SD after the completion of two cycles of late-line therapy.
Time frame: From the beginning of the treatment to the end of Cycle 2 (each cycle is 28 days) of treatment.
Progression-Free Survival
The survival time between the beginning of treatment to death or the progression.
Time frame: From date of recruitment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hunan Cancer Hospital